FDA Approves Nivolumab Plus Ipilimumab for Malignant Pleural Mesothelioma
October 3rd 2020The FDA approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for the frontline treatment of adults with unresectable, malignant, pleural mesothelioma (MPM), according to Bristol Myers Squibb, the manufacturer of the immunotherapy agents.